Polynucleotides
Polynucleotides are not dermal fillers: understanding the difference
Polynucleotides and dermal fillers are both injectable treatments, but they are chosen for different concerns. Understanding the distinction helps set realistic goals for skin quality, volume and facial contour.
The treatment goal is different
Polynucleotide treatment is generally discussed as a skin-quality approach. Depending on the product and treatment plan, the intended goals may include gradual improvement in hydration, texture, elasticity or the appearance of fine lines. It is not designed to create the immediate projection, contour or structural support associated with a dermal filler.
That difference matters when describing what bothers you. Skin that feels crepey or looks tired is not the same concern as loss of cheek volume, a recessed chin or a lip-shape request. One injectable treatment cannot be assumed to address every feature, and sometimes neither option is appropriate.
Temporary swelling is not facial volume
Multiple small injections may leave raised points, redness or localised swelling immediately afterwards. This can briefly make the skin look fuller or smoother, but it is a procedure reaction rather than the intended long-term result. It should not be judged as evidence that permanent volume has been added.
Polynucleotide results are assessed after the initial swelling has settled and usually across a planned course rather than straight after one appointment. Progress photographs are most useful when lighting, expression, camera position and timing are consistent. Even then, changes may be subtle and vary between people.
What the research can—and cannot—tell us
A 2025 systematic review found encouraging findings for wrinkles, texture and elasticity, but it included only nine studies involving 219 participants. The authors rated the available research as low or moderate quality and found variation in treatment areas, techniques and protocols. This limits how confidently results can be predicted for an individual patient.
A 2026 observational study reported improvements after a three-session course for the face, neck or décolletage, with no serious adverse events recorded. However, it studied one particular product without a randomised comparison group. Its results cannot prove that all polynucleotide products, schedules or injection techniques perform the same way.
Choosing according to the concern
A consultation should separate surface skin quality from changes in fat, bone support, muscle activity and skin laxity. If the main goal is replacement of lost volume or a defined alteration in contour, polynucleotides may not meet that expectation. If the concern is skin quality, adding facial volume may be unnecessary.
Combination treatment is not automatically better. Each additional procedure adds cost, downtime and risk. A staged plan makes it easier to judge the response and avoids treating an area simply because several options are available. Skincare, sun protection or no injectable treatment may form part of a sensible plan.
Downtime and adverse effects
Expected short-term effects can include tenderness, redness, swelling, bruising and small raised injection points. Less common problems may include infection, inflammation, persistent lumps or an allergic reaction. Product composition, treatment area, injection depth and individual health can all influence risk and recovery.
Contact the clinic promptly about severe or increasing pain, spreading redness or heat, marked swelling, discharge, fever, unusual skin colour or any unexpected deterioration. Sudden visual symptoms, breathing difficulty or features of a severe allergic reaction require urgent medical assessment rather than waiting for a routine review.
Suitability needs an individual assessment
Active infection or inflammation near the treatment area may mean postponing treatment. Pregnancy or breastfeeding, allergies, autoimmune or other medical conditions, medicines that affect bleeding and previous injectable reactions should be discussed. Suitability also depends on the specific product because formulations, source materials and instructions are not interchangeable.
Your practitioner should explain the intended purpose, alternatives, evidence limitations, likely downtime, follow-up and how to report a complication. The General Medical Council requires doctors to use current evidence about effectiveness and risk and to tell patients how adverse reactions can be reported. Consultation is therefore part of safe treatment, not a formality.